Mode
Text Size
Log in / Sign up
N/A N=103,117 Randomized Treatment

Trial of the Use of Antenatal Corticosteroids in Developing Countries

Preterm Birth

Enrolled (actual)
103,117
Serious AEs
5.7%
Results posted
Dec 2024
Primary outcome: Primary: Neonatal Mortality Rate at 28 Days in <5th Percentile Birth Weight Infants (as a Proxy Measure for Prematurity) — 566; 524 Participants — p=0.65

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Increasing use of Antenatal Corticosteroids (ACS) (Behavioral)
Age
Pediatric, Adult, Older Adult
Sex
Female
Sponsor
NICHD Global Network for Women's and Children's Health
Primary completion
Mar 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Neonatal Mortality Rate at 28 Days in <5th Percentile Birth Weight Infants (as a Proxy Measure for Prematurity)
566; 524 0.65
SECONDARY
Use of Antenatal Corticosteroids in Women at Risk of Preterm Birth in All the Study Clusters
1,052; 215 <0.0001 sig
SECONDARY
Suspected Maternal Infection
1,207; 867 <0.0001 sig
SECONDARY
Maternal Mortality Rate
106; 97
SECONDARY
Neonatal Mortality Rate
1300; 1211 0.0127 sig
SECONDARY
Stillbirth Mortality Rate
1304; 1264 0.0181 sig

Summary

Multi-country two-arm, parallel cluster randomized controlled trial to reduce neonatal mortality through increasing the rate of antenatal corticosteroid administration to eligible women.

Eligibility Criteria

This is an intent-to-treat design and thus all pregnancy outcomes of women who deliver in the study clusters and provide consent will be collected. Cluster-level inclusion criteria include

  • At least 250 deliveries per year.
  • Birth attendants within the health cluster will be consented to participate

Participant-level inclusion criteria include all pregnant women living in and delivering in the study cluster who:

  • Are between 24 and 36 weeks GA;
  • Present with signs of preterm labor, amniotic fluid leakage, hemorrhage, or hypertension;
  • Provide consent for injection or present to a facility where it is standard of care.

Exclusion Criteria

  • There will not be any specific exclusion criteria for clusters or participants.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01084096). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search